{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:48:36Z","timestamp":1792824516552,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40259-020-00451-w","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T10:02:45Z","timestamp":1603706565000},"page":"713-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Clinical Trials of IL-12\/IL-23 Inhibitors in Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Ahmed","family":"Almradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurij","family":"Hanzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-0338","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"451_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","volume":"10","author":"C Ott","year":"2013","unstructured":"Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585\u201395.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"451_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"451_CR3","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.","journal-title":"Clin Transl Gastroenterol."},{"key":"451_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","volume":"116","author":"Y Iwakura","year":"2006","unstructured":"Iwakura Y, Ishigame H. The IL-23\/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218\u201322.","journal-title":"J Clin Invest."},{"key":"451_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1172\/JCI21404","volume":"116","author":"D Yen","year":"2006","unstructured":"Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310\u20136.","journal-title":"J Clin Invest."},{"key":"451_CR6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461\u20133.","journal-title":"Science"},{"key":"451_CR7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016a;375:1946\u201360.","journal-title":"N Engl J Med."},{"key":"451_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med."},{"key":"451_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/07853890.2011.577093","volume":"43","author":"E Duvallet","year":"2011","unstructured":"Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011;43:503\u201311.","journal-title":"Ann Med."},{"key":"451_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719\u201329.","journal-title":"Nat Med."},{"key":"451_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65\u201370.","journal-title":"Gut"},{"key":"451_CR12","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","volume":"132","author":"CO Elson","year":"2007","unstructured":"Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359\u201370.","journal-title":"Gastroenterology"},{"key":"451_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","volume":"25","author":"HH Uhlig","year":"2006","unstructured":"Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309\u201318.","journal-title":"Immunity"},{"key":"451_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ng1954","volume":"39","author":"J Hampe","year":"2007","unstructured":"Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207\u201311.","journal-title":"Nat Genet."},{"key":"451_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/13543784.2018.1506764","volume":"27","author":"C Ma","year":"2018","unstructured":"Ma C, Jairath V, Khanna R, Feagan BG. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. Expert Opin Investig Drugs. 2018;27:649\u201360.","journal-title":"Expert Opin Investig Drugs."},{"key":"451_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016b;375:1946\u201360.","journal-title":"N Engl J Med."},{"key":"451_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","volume":"155","author":"P Rutgeerts","year":"2018","unstructured":"Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease. Gastroenterology. 2018;155:1045\u201358.","journal-title":"Gastroenterology"},{"issue":"1019\u201331","key":"451_CR18","first-page":"e7","volume":"157","author":"K Li","year":"2019","unstructured":"Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, et al. Effects of ustekinumab on histologic disease activity in patients with Crohn\u2019s disease. Gastroenterology. 2019;157(1019\u201331):e7.","journal-title":"Gastroenterology"},{"key":"451_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","volume":"42","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase II\/III clinical development programs. Drug Saf. 2019;42:751\u201368.","journal-title":"Drug Saf"},{"key":"451_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778\u201391.","journal-title":"MAbs."},{"key":"451_CR21","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D\u2019Haens G, Pan\u00e9s J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699\u2013709.","journal-title":"Lancet"},{"key":"451_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","volume":"3","author":"BG Feagan","year":"2018","unstructured":"Feagan BG, Pan\u00e9s J, Ferrante M, Kaser A, D\u2019Haens GR, Sandborn WJ, et al. Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3:671\u201380.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"451_CR23","doi-asserted-by":"publisher","first-page":"S024","DOI":"10.1093\/ecco-jcc\/jjz203.026","volume":"14","author":"M Ferrante","year":"2020","unstructured":"Ferrante M, Feagan BG, Pan\u00e9s J, Baert F, Lous E, Dewit O, et al. Long-term safety and efficacy of risankizumab treatment in patients with Crohn\u2019s disease: final results from the Phase 2 open-label extension study. J Crohns Colitis. 2020;14:S024-S25.","journal-title":"J Crohns Colitis"},{"key":"451_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/bph.12904","volume":"172","author":"K Kock","year":"2015","unstructured":"Kock K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, et al. Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015;172:159\u201372.","journal-title":"Br J Pharmacol"},{"issue":"77\u201386","key":"451_CR25","first-page":"e6","volume":"153","author":"BE Sands","year":"2017","unstructured":"Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study. Gastroenterology. 2017;153(77\u201386):e6.","journal-title":"Gastroenterology"},{"key":"451_CR26","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa033402","volume":"351","author":"PJ Mannon","year":"2004","unstructured":"Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn\u2019s disease. N Engl J Med. 2004;351:2069\u201379.","journal-title":"N Engl J Med"},{"key":"451_CR27","first-page":"1329","volume":"21","author":"R Panaccione","year":"2015","unstructured":"Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, et al. Briakinumab for treatment of Crohn\u2019s disease: results of a randomized trial. Inflamm Bowel Dis. 2015;21:1329\u201340.","journal-title":"Inflamm Bowel Dis."},{"issue":"537\u201349","key":"451_CR28","first-page":"e10","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(537\u201349):e10.","journal-title":"Gastroenterology"},{"key":"451_CR29","doi-asserted-by":"crossref","unstructured":"Pai R, Canavan J, Tuttle J, Durante M, Arora V, Milch C, et al. Histologic remission and mucosal healing in a phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis. Gastroenterology. 2020;158:S-1187.","DOI":"10.1016\/S0016-5085(20)33636-2"},{"issue":"20","key":"451_CR30","doi-asserted-by":"publisher","first-page":"31289\u20131","DOI":"10.1016\/j.cgh.2020.09.028","volume":"S1542\u20133565","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, et al. Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;S1542\u20133565(20):31289\u20131. https:\/\/doi.org\/10.1016\/j.cgh.2020.09.028.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"451_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-016-2110-5","volume":"72","author":"Y Zhuang","year":"2016","unstructured":"Zhuang Y, Calderon C, Marciniak SJ Jr, Bouman-Thio E, Szapary P, Yang TY, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72:1303\u201310.","journal-title":"Eur J Clin Pharmacol."},{"key":"451_CR32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135:1130\u201341.","journal-title":"Gastroenterology"},{"key":"451_CR33","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","volume":"391","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213\u201324.","journal-title":"Lancet"},{"key":"451_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjd.17454","volume":"180","author":"K Reich","year":"2019","unstructured":"Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180:1039\u201349.","journal-title":"Br J Dermatol."},{"key":"451_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388.","journal-title":"Lancet"},{"key":"451_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MIB.0000000000001212","volume":"23","author":"X Cheng","year":"2017","unstructured":"Cheng X, Taranath R, Lu L, Zhao L, Shah S, Foulke M, et al. The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, correlates with efficacy in preclinical models of IBD. Inflamm Bowel Dis. 2017;23:88.","journal-title":"Inflamm Bowel Dis."},{"key":"451_CR37","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.14309\/01.ajg.0000592540.43886.35","volume":"114","author":"X Cheng","year":"2019","unstructured":"Cheng X, Lee T, Ledet G, Zemade G, Tovera J, Campbell R, et al. Safety, tolerability, and pharmacokinetics of PTG-200, an oral GI-restricted peptide antagonist of IL-23 receptor, in normal healthy volunteers. Am J Gastroenterol. 2019;114:S439\u201340.","journal-title":"Am J Gastroenterol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00451-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00451-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00451-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:31:11Z","timestamp":1635208271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00451-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00451-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"assertion":[{"value":"26 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AA has no conflicts of interest to declare. JH has received speaker\u2019s fees from Biogen, Janssen, and Takeda. RS has no conflicts of interest to declare. CEP is an employee of Robarts Clinical Trials Inc. BGF has received grant\/research support from AbbVie Inc., Amgen Inc., AstraZeneca\/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc\/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc.\/Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, and UCB; consulting fees from Abbott\/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan\/Biogen, EnGene, Ferring Pharma, Roche\/Genentech, Galapagos, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, JnJ\/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestle, Nextbiotix, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., and Zyngenia; speakers bureau fees from Abbott\/AbbVie, JnJ\/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; is a scientific advisory board member for Abbott\/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan\/Biogen, Galapagos, Genentech\/Roche, JnJ\/Janssen, Merck, Nestle, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is the Senior Scientific Officer of Robarts Clinical Trials Inc. CM has received consulting fees from AbbVie, Janssen, Pfizer, Robarts Clinical Trials, and Takeda; and speaker\u2019s fees from AbbVie, Janssen, Pfizer, and Takeda. VJ has received consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena Pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials Inc., Topivert, and Celltrion; and speaker\u2019s fees from Takeda, Janssen, Shire, Ferring, Abbvie, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors made substantial contributions to drafting the manuscript and critically revising it for intellectual content.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}